Rheumatology Network is conducting a state of the practice survey for physicians and healthcare professionals who treat rheumatology patients. We'd like your feedback on issues and stressors that you and your patients face, such as the cost of healthcare to being overloaded with patients. Please take a moment to answer this multiple choice survey of just 15 questions.
Bone fracture patients should be managed by a multi-disciplinary clinical team that includes case management to ensure that patients are being properly and fully evaluated and treated for osteoporosis and the risk of future fractures, according to clinical recommendations issued on Friday by the a international group of experts speaking at the annual American Society for Bone and Mineral Research (ASBMR) meeting that took place over the weekend in Orlando.
Roche announced this week that the U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, a major morbidity of systemic lupus erythematosus (SLE).
Investigators are currently pursuing at least 50 possible new treatments, or treatment targets, for systemic lupus and lupus nephritis. We're tracking the studies and in this slideshow, we highlight the results from nine new studies on lupus nephritis.
In this Q&A, Dr. Roy Fleischmann, the primary investigator for the phase three clinical trial of upadacitinib (Rinvoq, AbbVie), compares the new rheumatoid arthritis treatment to other treatments.
An Indian-made biosimilar to adalimumab has been shown to be safe and effective for up to 24 weeks in patients with ankylosing spondylitis, say researchers writing in ACR Open Rheumatology this month.
Women with rheumatoid arthritis are concerned with pregnancy and parenting issues and require more information from their doctors, say researchers writing in ACR Open Rheumatology this month.
Fibromyalgia and polymyalgia rheumatica are distinctly different, but in a case report described in the May 8 issue of the American Journal of Case Reports, Fawad Aslam, M.D., of Mayo Clinic in Arizona, and colleagues describe a confusing case of a 30-year-old woman.
MRI-guided treat-to-target treatment for patients with rheumatoid arthritis is no better than conventional treat-to-target strategies, researchers reported in JAMA in February. However, in a new commentary posted this month in JAMA, researchers raise some interesting points experts may want to reconsider.
Vitamin D supplementation may not protect the heart from major adverse cardiovascular events, myocardial infarction, stroke or cardiovascular disease mortality, finds a study published in JAMA Cardiology.